272 related articles for article (PubMed ID: 37026714)
1. Emerging biologics for the treatment of pulmonary arterial hypertension.
Hye T; Hossain MR; Saha D; Foyez T; Ahsan F
J Drug Target; 2023 Jun; 31(5):1-15. PubMed ID: 37026714
[TBL] [Abstract][Full Text] [Related]
2. Bone morphogenetic protein signalling in pulmonary arterial hypertension: revisiting the BMPRII connection.
Li W; Quigley K
Biochem Soc Trans; 2024 Jun; 52(3):1515-1528. PubMed ID: 38716930
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory Antibodies against Activin A and TGF-β Reduce Self-Supported, but Not Soluble Factors-Induced Growth of Human Pulmonary Arterial Vascular Smooth Muscle Cells in Pulmonary Arterial Hypertension.
Kudryashova TV; Shen Y; Pena A; Cronin E; Okorie E; Goncharov DA; Goncharova EA
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30274147
[TBL] [Abstract][Full Text] [Related]
4. Altered bone morphogenetic protein and transforming growth factor-beta signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease.
Long L; Crosby A; Yang X; Southwood M; Upton PD; Kim DK; Morrell NW
Circulation; 2009 Feb; 119(4):566-76. PubMed ID: 19153267
[TBL] [Abstract][Full Text] [Related]
5. TGFβ and BMPRII signalling pathways in the pathogenesis of pulmonary arterial hypertension.
Tielemans B; Delcroix M; Belge C; Quarck R
Drug Discov Today; 2019 Mar; 24(3):703-716. PubMed ID: 30529762
[TBL] [Abstract][Full Text] [Related]
6. Impaired bone morphogenetic protein receptor II signaling in a transforming growth factor-β-dependent mouse model of pulmonary hypertension and in systemic sclerosis.
Gilbane AJ; Derrett-Smith E; Trinder SL; Good RB; Pearce A; Denton CP; Holmes AM
Am J Respir Crit Care Med; 2015 Mar; 191(6):665-77. PubMed ID: 25606692
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapies in pulmonary arterial hypertension.
Montani D; Chaumais MC; Guignabert C; Günther S; Girerd B; Jaïs X; Algalarrondo V; Price LC; Savale L; Sitbon O; Simonneau G; Humbert M
Pharmacol Ther; 2014 Feb; 141(2):172-91. PubMed ID: 24134901
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the prolyl isomerase Pin1 improves endothelial function and attenuates vascular remodelling in pulmonary hypertension by inhibiting TGF-β signalling.
Kurakula K; Hagdorn QAJ; van der Feen DE; Vonk Noordegraaf A; Ten Dijke P; de Boer RA; Bogaard HJ; Goumans MJ; Berger RMF
Angiogenesis; 2022 Feb; 25(1):99-112. PubMed ID: 34379232
[TBL] [Abstract][Full Text] [Related]
9. Activin-like kinase 5 (ALK5) mediates abnormal proliferation of vascular smooth muscle cells from patients with familial pulmonary arterial hypertension and is involved in the progression of experimental pulmonary arterial hypertension induced by monocrotaline.
Thomas M; Docx C; Holmes AM; Beach S; Duggan N; England K; Leblanc C; Lebret C; Schindler F; Raza F; Walker C; Crosby A; Davies RJ; Morrell NW; Budd DC
Am J Pathol; 2009 Feb; 174(2):380-9. PubMed ID: 19116361
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic potential of natural flavonoids in pulmonary arterial hypertension: A review.
Zhang JJ; Mao-Mao ; Shao MM; Wang MC
Phytomedicine; 2024 Jun; 128():155535. PubMed ID: 38537442
[TBL] [Abstract][Full Text] [Related]
11. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension.
Hoeper MM; Badesch DB; Ghofrani HA; Gibbs JSR; Gomberg-Maitland M; McLaughlin VV; Preston IR; Souza R; Waxman AB; Grünig E; Kopeć G; Meyer G; Olsson KM; Rosenkranz S; Xu Y; Miller B; Fowler M; Butler J; Koglin J; de Oliveira Pena J; Humbert M;
N Engl J Med; 2023 Apr; 388(16):1478-1490. PubMed ID: 36877098
[TBL] [Abstract][Full Text] [Related]
12. Emerging pharmacotherapies for the treatment of pulmonary arterial hypertension.
Auth R; Klinger JR
Expert Opin Investig Drugs; 2023; 32(11):1025-1042. PubMed ID: 37881882
[TBL] [Abstract][Full Text] [Related]
13. Receptor for activated C-kinase 1, a novel interaction partner of type II bone morphogenetic protein receptor, regulates smooth muscle cell proliferation in pulmonary arterial hypertension.
Zakrzewicz A; Hecker M; Marsh LM; Kwapiszewska G; Nejman B; Long L; Seeger W; Schermuly RT; Morrell NW; Morty RE; Eickelberg O
Circulation; 2007 Jun; 115(23):2957-68. PubMed ID: 17515463
[TBL] [Abstract][Full Text] [Related]
14. Is sotatercept, which traps activins and growth differentiation factors, a new dawn in treating pulmonary arterial hypertension (PAH)?
Doggrell SA
Expert Opin Biol Ther; 2023; 23(7):589-593. PubMed ID: 37269300
[TBL] [Abstract][Full Text] [Related]
15. Inactivating the Uninhibited: The Tale of Activins and Inhibins in Pulmonary Arterial Hypertension.
Ryanto GRT; Musthafa A; Hara T; Emoto N
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834742
[TBL] [Abstract][Full Text] [Related]
16. Extracellular vesicle cross-talk between pulmonary artery smooth muscle cells and endothelium during excessive TGF-β signalling: implications for PAH vascular remodelling.
de la Cuesta F; Passalacqua I; Rodor J; Bhushan R; Denby L; Baker AH
Cell Commun Signal; 2019 Nov; 17(1):143. PubMed ID: 31703702
[TBL] [Abstract][Full Text] [Related]
17. An emerging class of new therapeutics targeting TGF, Activin, and BMP ligands in pulmonary arterial hypertension.
Upton PD; Dunmore BJ; Li W; Morrell NW
Dev Dyn; 2023 Mar; 252(3):327-342. PubMed ID: 35434863
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Approaches for Treating Pulmonary Arterial Hypertension by Correcting Imbalanced TGF-β Superfamily Signaling.
Andre P; Joshi SR; Briscoe SD; Alexander MJ; Li G; Kumar R
Front Med (Lausanne); 2021; 8():814222. PubMed ID: 35141256
[TBL] [Abstract][Full Text] [Related]
19. The role of TGF-β or BMPR2 signaling pathway-related miRNA in pulmonary arterial hypertension and systemic sclerosis.
Xu B; Xu G; Yu Y; Lin J
Arthritis Res Ther; 2021 Nov; 23(1):288. PubMed ID: 34819148
[TBL] [Abstract][Full Text] [Related]
20. New Mutations and Pathogenesis of Pulmonary Hypertension: Progress and Puzzles in Disease Pathogenesis.
Aldred MA; Morrell NW; Guignabert C
Circ Res; 2022 Apr; 130(9):1365-1381. PubMed ID: 35482831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
